Core Insights - GaoShi Medical's subsidiary GaoShi Innovation Technology has received approval for its "Frequency Domain Biometer" from the Jiangsu Provincial Drug Administration, marking a significant advancement in the company's product offerings [1][2] - The demand for myopia prevention and control is rapidly increasing in China, with the overall myopia rate among youth at approximately 53.6% according to the National Health Commission's "China Eye Health White Paper" [1] - The myopia prevention market in China has seen substantial growth, reaching a market size of RMB 14.68 billion in 2023, representing a year-on-year increase of 43.2% [1] Company Insights - The Frequency Domain Biometer, with registration number SuXieZhuZhun 20252161508, is developed based on a new generation of frequency domain measurement principles, offering higher resolution, faster imaging speed, and better signal-to-noise ratio compared to traditional time-domain products [2] - The device features an innovative dual optical path design, allowing for real-time cross-sectional imaging of the cornea, retina, and choroid during eye parameter measurements, which aids in monitoring myopia progression and screening for complications [2] - GaoShi Innovation has independently developed the device over two years, achieving 100% localization of key optical, mechanical, and electrical components [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 2023年國家衛健委發佈的《中國眼健康白皮書》指出，中國青少年總體近視率約 為53.6%。隨著近視群體的不斷擴大，近視防控需求的市場也迅速增加。沙利 文發佈的《中國眼鏡鏡片行業研究白皮書》指出，近年來我國近視防控市場規 模不斷增長，2022年後開始加速，2023年市場規模已經達到人民幣146.8億元， 同比增長43.2%。生物測量儀是近視防控的關鍵設備，能夠對眼軸長度、角膜 曲率、晶體厚度等進行微米級的精確測量，從而能夠在監測青少年近視進展、 評估近視防控手段的療效等方面起到重要作用，同時也是近視屈光手術術前 精準評估必不可少的設備之一。 – 1 – 高視創新本次獲批的頻域生物測量儀（註冊證編號：蘇械注准20252161508）， 基 ...